|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Entire Cohort  (n=12162) | Beta 3 Agonist  (n=4329) | Anticholinergic  (n=7833) | *p* |
| Age, *years* | 68 (+0.53) | 69 (+0.58) | 67 (+0.51) | <0.001 |
| Race  White  Black/African American  Asian  None of the above | 5724 (47.0%)  4105 (33.8%)  183 (1.5%)  2150 (17.7%) | 2816 (65.1%)  688 (15.9%)  67 (1.5%)  758 (17.5%) | 2908 (37.1%)  3417 (43.6%)  116 (1.5%)  1392 (17.8%) | <0.001 |
| Ethnicity  Hispanic  Not Hispanic  None of the above | 742 (6.1%)  9388 (77.2%)  2032 (16.7%) | 237 (5.4%)  3468 (80.1%)  624 (14.5%) | 505 (6.4%)  5920 (75.6%)  1408 (18.0%) | <0.001 |
| Insurance  Medicaid/Medicare  Private  Self-pay | 7346 (60.4%)  4773 (39.2%)  43 (0.4%) | 2766 (63.9%)  1547 (35.7%)  16 (0.4%) | 4580 (58.5%)  3226 (41.2%)  27 (0.3%) | <0.001 |
| Clinician Specialty  Urogynecology  Urology  Obstetrics/Gynecology  Primary Care | 2647 (21.8%)  2586 (21.2%)  2944 (24.2%)  3985 (32.8%) | 1463 (33.8%)  995 (23.0%)  910 (21.0%)  961 (22.2%) | 1184 (15.1%)  1591 (20.3%)  2034 (26.0%)  3024 (38.6%) | <0.001 |